Boc-Lys(Boc)-OPFP | 85535-59-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Boc-Lys(Boc)-OPFP
• 英文别名: pentafluorophenyl N-α-N-ε-di-Boc-L-lysinate
• CAS: 85535-59-7
• 化学式: C₂₂H₂₉F₅N₂O₆
• 分子量: 512.474
• InChiKey: ONHYHYKREWZRIO-NSHDSACASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.88
• 重原子数：
  35.0
• 可旋转键数：
  8.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  102.96
• 氢给体数：
  2.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  Boc-Lys(Boc)-OPFP 在 氨 作用下， 以 甲醇 为溶剂， 以74%的产率得到Boc-Lys(Boc)-NH2
  参考文献：
  名称：

  Sodium-liquid ammonia reduction of carboxamides to alcohols

  摘要：

  DOI：

  10.1021/jo00159a030
• 作为产物：
  描述：

  五氟苯酚 在 吡啶 、 氯化亚砜 作用下， 以 乙醚 为溶剂， 反应 0.5h， 生成 Boc-Lys(Boc)-OPFP
  参考文献：
  名称：

  Bis(pentaluorophenyl) sulfite ? A new reagent for the synthesis of activated pentafluorophenyl esters of N-protected amino acids

  摘要：

  DOI：

  10.1007/bf00952635

文献信息

• Chemokine receptor binding heterocyclic compounds
  申请人：AnorMED, Inc.

  公开号：US06750348B1

  公开（公告）日：2004-06-15

  This invention relates to a novel class of heterocyclic compounds that bind chemokine receptors, inhibiting the binding of their natural ligands thereby. These compounds result in protective effects against infection by HIV through binding to chemokine receptors, including CXCR4 and CCR5, thus inhibiting the subsequent binding by these chemokines. The present invention provides a compound of Formula I wherein, W is a nitrogen atom and Y is absent or, W is a carbon atom and Y═H; R1 to R7 may be the same or different and are independently selected from hydrogen or straight, branched or cyclic C1-6 alkyl; R8 is a substituted heterocyclic group or a substituted aromatic group Ar is an aromatic or heteroaromatic ring each optionally substituted at single or multiple, non-linking positions with electron-donating or withdrawing groups; n and n′ are independently, 0-2; X is a group of the formula: Wherein, Ring A is an optionally substituted, saturated or unsaturated 5 or 6-membered ring, and P is an optionally substituted carbon atom, an optionally substituted nitrogen atom, sulfur or oxygen atom. Ring B is an optionally substituted 5 to 7-membered ring. Ring A and Ring B in the above formula can be connected to the group W from any position via the group V, wherein V is a chemical bond, a (CH2)n″ group (where n″=0-2) or a C═O group. Z is, (1) a hydrogen atom, (2) an optionally substituted C1-6 alkyl group, (3) a C0-6 alkyl group substituted with an optionally substituted aromatic or heterocyclic group, (4) an optionally substituted C0-6 alkylamino or C3-7 cycloalkylamino group, (5) an optionally substituted carbonyl group or sulfonyl. These compounds further include any pharmaceutically acceptable acid addition salts and metal complexes thereof and any stereoisomeric forms and mixtures of stereoisomeric forms thereof.

  这项发明涉及一类新型的杂环化合物，它们结合趋化因子受体，抑制其天然配体的结合。这些化合物通过结合趋化因子受体，包括CXCR4和CCR5，从而抑制这些趋化因子的后续结合，产生对HIV感染的保护效果。本发明提供了一个式I的化合物 其中，W是氮原子，Y不存在，或者W是碳原子，Y═H； R1至R7可以相同也可以不同，并且独立地选择自氢或直链、支链或环状的C1-6烷基； R8是一个取代的杂环基或取代的芳香基 Ar是一个芳香或杂芳环，每个环在单个或多个非连接位置可选择地取代有电子给体或吸引体基团； n和n′独立地为0-2； X是下式的一个基团： 其中，环A是一个可选择地取代的饱和或不饱和的5或6元环，P是一个可选择地取代的碳原子、一个可选择地取代的氮原子、硫或氧原子。环B是一个可选择地取代的5到7元环。上述式中的环A和环B可以通过基团V从任何位置连接到基团W，其中V是一个化学键，一个(CH2)n″基团（其中n″=0-2）或一个C═O基团。Z是(1)一个氢原子，(2)一个可选择地取代的C1-6烷基基团，(3)一个用可选择地取代的芳香或杂环基团取代的C0-6烷基基团，(4)一个可选择地取代的C0-6烷基氨基或C3-7环烷氨基基团，(5)一个可选择地取代的羰基或磺酰基。这些化合物还包括任何药学上可接受的酸盐和金属络合物，以及它们的任何立体异构体形式和立体异构体形式的混合物。
• Molecularly Precise Dendrimer-Drug Conjugates with Tunable Drug Release for Cancer Therapy
  作者：Zhuxian Zhou、Xinpeng Ma、Caitlin J. Murphy、Erlei Jin、Qihang Sun、Youqing Shen、Edward A. Van Kirk、William J. Murdoch

  DOI：10.1002/anie.201406442

  日期：2014.10.6

  The structural preciseness of dendrimers makes them perfect drug delivery carriers, particularly in the form of dendrimer–drug conjugates. Current dendrimer–drug conjugates are synthesized by anchoring drug and functional moieties onto the dendrimer peripheral surface. However, functional groups exhibiting the same reactivity make it impossible to precisely control the number and the position of the

  树枝状大分子的结构精确度使其成为理想的药物输送载体，尤其是树枝状大分子-药物结合物的形式。当前的树状聚合物-药物缀合物是通过将药物和功能部分锚定在树状聚合物的外周表面上而合成的。然而，表现出相同反应性的官能团使得不可能精确控制锚定在树枝状聚合物表面上的官能团和药物分子的数量和位置。这种结构上的异质性导致可变的药代动力学，从而阻止了这种缀合物的翻译。此外，锚定在树枝状聚合物外围的高度疏水的药物分子可与血液成分相互作用并改变药代动力学行为。为了解决这些问题，我们在这里报道了分子精确的树状聚合物-药物缀合物，其中药物部分掩埋在树状聚合物中。出人意料的是，这些缀合物的药物释放速率可通过树枝状聚合物的产生，表面化学性质和酸度来调节。
• DNA Scission Chemistry and EPR Studies of Four New Bis(2,6-Dimethoxyhydroquinone - 3-Mercaptoacetic Acid) - Peptide Conjugates
  作者：Yu-Fei Song

  DOI：10.1071/ch03111

  日期：——

  In an effort to investigate the use of short peptide chains as carriers of new antitumour agents, four tripeptide cytotoxic agent conjugates, namely DMQ–MA–Lys(DMQ–MA)–Lys(Cbz)–Arg–OMe, DMQ–MA–Lys(DMQ–MA)–Phe–Arg–OMe, DMQ–MA–Lys(DMQ–MA)–Ile–Arg–OMe, and DMQ–MA–Lys(DMQ–MA)–Val–Arg–OMe, were synthesized. The cytotoxic agent conjugated to the N-terminal, and the ξ-amino group of lysine of the tripeptides

  为了研究使用短肽链作为新型抗肿瘤剂的载体，四种三肽细胞毒剂偶联物，即 DMQ-MA-Lys(DMQ-MA)-Lys(Cbz)-Arg-OMe、DMQ-MA-Lys (DMQ–MA)–Phe–Arg–OMe、DMQ–MA–Lys(DMQ–MA)–Ile–Arg–OMe 和 DMQ–MA–Lys(DMQ–MA)–Val–Arg–OMe 被合成。与 N 末端缀合的细胞毒剂和三肽赖氨酸的 ξ-氨基是 2,6-二甲氧基氢醌-3-巯基乙酸 (DMQ-MA)。根据 Pfp/DCC 方法（其中 Pfp 指五氟苯酚， DCC 指 N,N'-二环己基碳二亚胺），通过在溶液中偶联受保护的氨基酸残基来合成三肽。DNA 断裂化学表明，这些化合物能够在药物浓度低至 5–20 μM 的情况下将超螺旋 DNA 切割成开环形式，而无需添加 H2O2 或紫外线照射。当羟基自由基清除剂如甘油和苯甲酸钠加入反应体系时，DNA 切
• Molecularly Precise, Bright, Photostable, and Biocompatible Cyanine Nanodots as Alternatives to Quantum Dots for Biomedical Applications
  作者：Jiajia Yang、Kaiqi Wang、Yihuan Zheng、Ying Piao、Jinqiang Wang、Jianbin Tang、Youqing Shen、Zhuxian Zhou

  DOI：10.1002/anie.202202128

  日期：2022.9.5

  Cyanine nanodots constructed by step-by-step divergent synthesis of cyanine dye-cored polylysine dendrimers possess many of the merits of quantum dots and organic fluorophores, including precise structure, well-defined size, strong and stable fluorescence, and a customizable fluorescence spectrum. A strategy is described for synthesis of various precise fluorescent nanoparticles with optical properties

  以花青染料为核心的聚赖氨酸树枝状大分子分步发散合成所构建的花青纳米点具有量子点和有机荧光团的许多优点，包括结构精确、尺寸明确、荧光强且稳定，以及可定制的荧光光谱。描述了一种合成具有与生物医学应用相关的光学特性的各种精确荧光纳米粒子的策略。
• Dendritic Macromers as in Situ Polymerizing Biomaterials for Securing Cataract Incisions
  作者：Michel Wathier、Pil J. Jung、Michael A. Carnahan、Terry Kim、Mark W. Grinstaff

  DOI：10.1021/ja045870l

  日期：2004.10.1

  Dendritic macromers are attractive macromolecules for hydrogel formation since high cross-linking densities at low polymer concentration can be obtained, varied physical properties can be observed based on the macromer structure, and low viscous aqueous solutions can be injected in an in vivo site of irregular shaped to form a well-integrated polymer network. A peptide dendron possessing terminal cysteine residues was synthesized and characterized. When this peptide dendron was mixed with poly(ethylene glycol dialdehyde) in aqueous solution at pH = 7.4, a hydrogel spontaneously formed as a consequence of thiazolidine linkages between the macromers. Such in situ polymerized hydrogels are of interest for tissue engineering and wound-repair applications. To evaluate the potential use of this hydrogel sealant in ophthalmic surgeries, a 3-mm clear corneal incision (i.e., the wounds created during a typical cataract surgery) was successfully sealed.